EHA 2016 | The importance of diagnosing DLBCL on a molecular level and how it will improve treatment

Georg Lenz

Georg Lenz, MD, PhD, from the University of Münster, Münster, Germany discusses the clinical significance of diagnosing diffuse large B-cell lymphoma (DLBCL) on a molecular level at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Lenz mentions how treatment can become specific by utilizing genetics and introducing novel inhibitors that target specific signaling pathways. He holds the optimism that this can improve survival for affected patients.

Share this video